175867-52-4

Upstream product

• 3114-70-3 trans-1,4-diaminocyclohexane 
• 76-83-5 trityl chloride 

Downstream Products

• 174774-99-3 di-tert-butyl trans-[4-(triphenylmethylamino)cyclohexylamino]diacetate 
• 174775-01-0 di-tert-butyl trans-(4-aminocyclohexylamino)diacetate 
• 259150-16-8 di-tert-butyl trans-[4-(5-amidinobenzofuran-2-carboxamido)cyclohexylamino]diacetate 
• 174774-32-4 di-tert-butyl trans-[4-[5-(benzyloxycarbonylamidino)benzofuran-2-carboxamido]cyclohexylamino]diacetate 

Relevant academic research and scientific papers

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

A novel series of platelet receptor glycoprotein (Gp) IIb/IIIa antagonists with condensed heterocycles as their basic core was synthesized. In an in vitro assay, trans-4-(5-amidinobenzofuran-2- carboxamido)cyclohexyl]oxyacetic acid 17e and trans-3-[4-(5-

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases